Chardan Capital Initiates Coverage On Gossamer Bio with Buy Rating, Announces Price Target of $160

Chardan Capital analyst Andreas Argyrides has initiated coverage on Gossamer Bio (NASDAQ: GOSS) with a Buy rating. The firm has set a price target of $160 for the company's stock.